AIM

SEC Filing Summary: Hemispherx BioPharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2001. Hemispherx BioPharma, Inc. is a pharmaceutical research and development company focused on nucleic acid technologies. Its primary development effort centers on Ampligen, an investigational drug for treating viral diseases (including HIV and Hepatitis) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The company is currently conducting a Phase III clinical trial for ME/CFS involving 230 patients.

Key Financial Metrics

Liquidity: Cash and short-term investments totaled approximately $6.1 million as of March 31, 2001. The company reported a net cash decrease of $1.66 million for the quarter, driven primarily by operating activities consuming $2.2 million.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by $508,000 (26%) compared to Q1 2000, primarily due to higher R&D spending.
• R&D Expenses: Increased by $342,000. This was driven by $213,000 in increased manufacturing and quality assurance costs for Ampligen production and $145,000 in raw material purchases to support pilot production runs.
• Revenue Decline: Cost recovery revenues dropped $83,000 due to a strategic shift in focus toward recruiting patients for the Phase III ME/CFS trial and initiating new HIV studies.
• Non-Cash Charges: Stock/warrant compensation expense increased to $262,000 from $155,000 due to the extension of expiration dates on certain non-public warrants.
• Investment Losses: The company recorded a $25,000 equity loss from its investment in the California Institute of Molecular Medicine (CIMM).

Outlook, Risks, and Contingencies

Management Commentary & Outlook: Management anticipates continued losses as the company invests in clinical trials and regulatory approval processes. Future profitability is uncertain and dependent on FDA approval of Ampligen. The company expects to require substantial additional financing through equity or debt to complete development and commercialization.

Key Risks:

• Regulatory Approval: Ampligen has not received FDA approval for commercial sale. Failure to demonstrate safety and efficacy in clinical trials would materially adversely affect operations.
• Liquidity: The company has an accumulated deficit of over $85 million and relies on cost recovery revenues and warrant exercises, which are subject to market conditions.
• Manufacturing: The company lacks commercial-scale manufacturing capacity and relies on third-party suppliers or future facility construction.
• Patent Protection: Success depends on obtaining and enforcing patents, which involves significant legal uncertainty and potential litigation.

Legal Proceedings:

• Asensio Litigation: Ongoing multi-count litigation involving defamation and interference claims with Manuel P. Asensio and Asensio & Company, Inc. in Pennsylvania and New York courts. A trial is scheduled for August 2001 in Pennsylvania.
• Cook Imaging Corp.: A dispute regarding unpaid invoices for Ampligen manufacturing ($250,000 claimed by Cook) and a counterclaim by Hemispherx for $1 million related to alleged Good Manufacturing Practice (cGMP) deviations. Trial rescheduled for May 2001.

Investor Verification Checklist

• Verify the status and enrollment numbers of the Phase III ME/CFS clinical trial for Ampligen.
• Confirm the timeline and likelihood of FDA regulatory approval for Ampligen.
• Assess the company's cash runway given the $2.2 million quarterly operating burn rate and $6.1 million in liquid assets.
• Review the outcomes of the pending litigation with Asensio & Company and Cook Imaging Corp.
• Monitor the exercise rate of Class A Redeemable Warrants and the company's ability to raise additional capital without excessive dilution.